WALTHAM, Mass., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced its support for the patient and research communities in recognition of Rare Disease Day 2018.
“At Chiasma, we are focused on improving the lives of patients who face challenges associated with existing treatments for their rare and debilitating diseases,” said Mark Fitzpatrick, president and CEO of Chiasma. “The theme for Rare Disease Day 2018 is ‘research’ – and for good reason. Last year, rare or orphan disease treatments accounted for nearly 40% of all new drugs approved by the FDA -- all to the benefit of the patients and their families who desperately need treatments. For this reason, we also pay tribute to the patient community, which makes our drug development efforts so meaningful. We strongly believe in our own mission, to enhance the lives of adult patients living with acromegaly, and we join with policy makers, researchers, companies and healthcare professionals in the drive to increasingly and more effectively involve patients in rare disease research.”
Rare Disease Day takes place on the last day of February each year. The main objective is to raise awareness among the general public and decision-makers about rare diseases and their impact on patients' lives. For more information about Rare Disease Day, please visit www.rarediseaseday.org.
Chiasma is focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. The Company recently initiated CHIASMA OPTIMAL, its third Phase 3 clinical trial for its octreotide capsules product candidate, conditionally trade-named MYCAPSSA®, for the maintenance therapy of adult patients with acromegaly in whom prior treatment with somatostatin analogs has been shown to be effective and tolerated following SPA agreement with the FDA on the design of the trial. Chiasma is headquartered in Waltham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma. For more information, please visit the Company’s website at www.chiasma.com.
Sharon Merrill Associates